These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28689146)

  • 1. Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.
    Zaware N; Zhou MM
    Curr Opin Chem Biol; 2017 Aug; 39():116-125. PubMed ID: 28689146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bromodomain: from epigenome reader to druggable target.
    Sanchez R; Meslamani J; Zhou MM
    Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine.
    Engelberg IA; Foley CA; James LI; Frye SV
    Curr Opin Chem Biol; 2021 Aug; 63():132-144. PubMed ID: 33852996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of epigenetic reader domains.
    Greschik H; Schüle R; Günther T
    Expert Opin Drug Discov; 2017 May; 12(5):449-463. PubMed ID: 28277835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between chromatin acetylation and SUMOylation of tripartite motif-containing protein 24 (TRIM24) impacts cell adhesion.
    Appikonda S; Thakkar KN; Shah PK; Dent SYR; Andersen JN; Barton MC
    J Biol Chem; 2018 May; 293(19):7476-7485. PubMed ID: 29523690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential.
    Yu L; Wang Z; Zhang Z; Ren X; Lu X; Ding K
    Curr Top Med Chem; 2015; 15(8):776-94. PubMed ID: 25732788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer.
    Gong F; Chiu LY; Miller KM
    PLoS Genet; 2016 Sep; 12(9):e1006272. PubMed ID: 27631103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain Histone Readers and Cancer.
    Jain AK; Barton MC
    J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hitting the 'mark': interpreting lysine methylation in the context of active transcription.
    Wozniak GG; Strahl BD
    Biochim Biophys Acta; 2014 Dec; 1839(12):1353-61. PubMed ID: 24631869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecular modulators of cancer-associated epigenetic mechanisms.
    Itoh Y; Suzuki T; Miyata N
    Mol Biosyst; 2013 May; 9(5):873-96. PubMed ID: 23511667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone peptide microarray screen of chromo and Tudor domains defines new histone lysine methylation interactions.
    Shanle EK; Shinsky SA; Bridgers JB; Bae N; Sagum C; Krajewski K; Rothbart SB; Bedford MT; Strahl BD
    Epigenetics Chromatin; 2017; 10():12. PubMed ID: 28293301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting epigenetic reader domains by chemical biology.
    Cipriano A; Sbardella G; Ciulli A
    Curr Opin Chem Biol; 2020 Aug; 57():82-94. PubMed ID: 32739717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
    Chaidos A; Caputo V; Karadimitris A
    Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the development of peptide-based inhibitors targeting epigenetic readers of histone lysine acetylation and methylation marks.
    Liu S; Li X; Li X; Li XD
    Curr Opin Chem Biol; 2023 Aug; 75():102334. PubMed ID: 37263048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.